[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 79 of about 79
1. Sanada Y, Yoshida K: A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes. J Gastrointestin Liver Dis; 2008 Dec;17(4):457-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes.
  • Here we report a case of benign intraductal papillary-mucinous neoplasm (IPMN) of the pancreas containing two major subtypes.
  • Histopathologic examinations revealed that IPMN was composed of gastric-type adenoma and intestinal-type borderline lesion.
  • Marked intraluminal nodular growth was observed in the center of the tumor composed of intestinal-type cells positive for MUC2.
  • Our observations suggest that gastric-type epithelium is a precursor of intestinal-type lesions in the stepwise progression of IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Mixed Tumor, Malignant / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastrointestin Liver Dis. 2009 Jun;18(2):251-2 [19565062.001]
  • (PMID = 19104710.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mucin-2
  •  go-up   go-down


2. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


3. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


Advertisement
4. Angeles-Angeles A: [Endocrine neoplasm of the stomach. Study of thirteen cases]. Gac Med Mex; 2005 May-Jun;141(3):207-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine neoplasm of the stomach. Study of thirteen cases].
  • [Transliterated title] Tumores endocrinos del estómago. Análisis de 13 casos.
  • A Thirteen patients with primary endocrine neoplasm of the stomach were studied for 20 years.
  • These two forms of neoplasm showed important differences: those associated with atrophic gastritis had hypergastrinemia, all of the multiple small tumors confined to the corpus and fundus were well differentiated carcinoids associated with intestinal metaplasia and G cell hyperplasia in antrum and ECL cell hyperplasia in corpus and fundus.
  • Tumors were clinically benign, with an excellent prognosis.
  • All patients are currently alive with no evidence of neoplasm.
  • In only one of these cases, antiparietal cell antibodies were documented; in three of them, extensive intestinal metaplasia probably due to Helicobacter pylori infection was found.
  • In contrast, sporadic carcinoids were large isolated tumors originating in the antrum or corpus.
  • Two patients died as a consequence of the neoplasm; all of them were moderately differentiated and in none of the cases we found evidence of endocrine hyperplasia.
  • Al four neuroendocrine carcinomas had a clinical course similar to that of gastric adenocarcinomas and were poorly differentiated large tumors.
  • [MeSH-major] Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025986.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


5. Beltran MA, Cruces KS: Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study. Int J Surg; 2007 Jun;5(3):183-91
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study.
  • BACKGROUND: Small-bowel tumors are rare and account for 1-2% of all gastrointestinal neoplasms.
  • Most of these tumors are found at surgery indicated for other diagnosis or intestinal obstruction.
  • The rarity, unclear presentation and diagnostic difficulty of these tumors stimulated our interest to review our experience with emergency surgery for intestinal obstruction secondary to jejunoileal tumors.
  • METHODS: We reviewed 17 patients operated on for intestinal obstruction secondary to benign and malignant primary tumors of jejunum and ileum at our institution the last 10 years.
  • The most frequent tumors found were GIST (36%) followed by lymphomas (24%) and adenocarcinomas (18%).
  • Most tumors (65%) were located in the ileum.
  • Mean survival for patients with malignant tumors was 19.5+/-13 months, and for patients with benign tumors 72+/-20 months (p<0.05).
  • CONCLUSION: Jejunoileal tumors present frequently in patients younger than 49 years of age.
  • Ileal tumors are more likely to develop intestinal obstruction than jejunal tumors.
  • [MeSH-major] Ileal Neoplasms / complications. Intestinal Obstruction / etiology. Jejunal Neoplasms / complications
  • [MeSH-minor] Abdomen, Acute / etiology. Adenocarcinoma / complications. Adult. Aged. Case-Control Studies. Female. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / pathology. Humans. Leiomyoma / complications. Logistic Models. Lymphoma / complications. Lymphoma / pathology. Male. Middle Aged. Neoplasm Staging. Sarcoma / complications

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509501.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Jausset F, Delvaux M, Dumitriu D, Bressenot A, Bruot O, Mathias J, Regent D, Laurent V: Benign intraductal papillary-mucinous neoplasm of the pancreas associated with spontaneous pancreaticogastric and pancreaticoduodenal fistulas. Digestion; 2010;82(1):42-6
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign intraductal papillary-mucinous neoplasm of the pancreas associated with spontaneous pancreaticogastric and pancreaticoduodenal fistulas.
  • Invasive intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas may be associated with pancreaticogastric fistulas as shown by case reports.
  • We report the case of a benign IPMN associated with pancreaticogastric and pancreaticoduodenal fistulas.
  • A 70-year-old woman was admitted with intestinal obstruction.
  • Computed tomography and MRI showed a large dilatation of the main pancreatic duct (>1 cm) with intraductal nodules, and pancreaticogastric and pancreaticoduodenal fistulas.
  • The histopathological examination of the surgical specimen showed a benign IPMN.
  • This case proves that a benign IPMN can cause pancreaticogastric and pancreaticoduodenal fistulas, probably resulting from mechanical factors.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Carcinoma, Papillary / complications. Duodenal Diseases / etiology. Gastric Fistula / etiology. Intestinal Fistula / etiology. Pancreatic Fistula / etiology. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 S. Karger AG, Basel.
  • (PMID = 20203511.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Kim SY, Jeon TJ, Hong JH, Kim GS, Oh TH, Seo DD, Shin WC, Choi WC: [An adult case of small bowel intussusception caused by hemangioma presenting with intestinal bleeding]. Korean J Gastroenterol; 2008 Sep;52(3):183-7
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An adult case of small bowel intussusception caused by hemangioma presenting with intestinal bleeding].
  • Unlike childhood intussusception, adult intussusception has an identifiable leading lesion such as malignant or benign neoplasm.
  • There were few cases of small bowel intussusception caused by hemangioma in adults, but those reports were presented with abdominal pain.
  • This report describes a 65-year-old female who suffered from small bowel intussusception caused by hemangioma presenting with intestinal bleeding.
  • Abdominal computed tomography showed the target sign of small bowel with a leading point of mass.
  • This mass turned out to be a hemangioma after the small bowel resection.
  • Therefore, small bowel intussusception by hemangioma should be also considered as a bleeding focus when an adult patient presented intestinal bleeding without bleeding focus in the stomach and colon.
  • Herein we report a case of small bowel intussusception caused by hemangioma presenting with intestinal bleeding.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Hemangioma / complications. Intestinal Neoplasms / complications. Intestine, Small. Intussusception / diagnosis

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077515.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


8. Mongardini M, Iachetta RP, Cola A, Brunelli D, Degli Effetti E, Blasi S, Maturo A, Benedetti F, Custureri F: [Gastric lipoma presenting as intestinal obstruction]. G Chir; 2006 Mar;27(3):90-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric lipoma presenting as intestinal obstruction].
  • Gastric lipoma is a rare benign tumor.
  • The symptoms are correlated with the size and the dimensions of neoplasm.
  • It can be the cause of bleeding, gastroduodenal intussusception and intestinal obstruction, as in case reported and surgically treated.
  • [MeSH-major] Intestinal Obstruction / etiology. Lipoma / complications. Lipoma / diagnosis. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681867.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • However, borderline OInMTs are usually large and heterogeneous, and the standard sampling protocol for them is not evidence based.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Yang WL, Zhang XC, Yan ZQ, Zhang HM, Zhao Z, Zhang JG, Wang YJ: [Clinical analysis of primary small intestinal neoplasms in 305 cases]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):781-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary small intestinal neoplasms in 305 cases].
  • OBJECTIVE: To summarive the experience in diagnosis and treatment of primary small intestinal neoplasm.
  • METHODS: The data of 305 patients with pathologically confirmed primary small intestinal tumor collected from 6 hospitals around the Songhua River during the past 33 years were analyzed retrospectively.
  • RESULTS: There were 42 benign and 263 malignant tumors in this series with a ratio of 1: 6.26.
  • The 263 malignant tumors in this series consisted of 135 adenocarcinomas, 57 malignant stromal tumors, 37 malignant lymphomas, 20 carcinoids, and etc.
  • Chronic occult bleeding, gradual of body weight loss and mild abdominal pain (three obscurities) were the common clinical features and alerting massage of intestinal tumor.
  • Correct preoperative diagnostic rate was only 57.0% (174/305) due to difficulty in early diagnosis, which was 67.2% (92/137) in the duodenal tumors, and 51.9% (82/168) in the jejunoileal tumors.
  • All of the 42 benign tumors were resected completely.
  • For the 263 patients with malignant tumors, radical dissection was performed in 153, palliative resection in 34, and gut by-pass or biopsy in 76.
  • The median survival of the patients who underwent radical resection of their malignant tumors was 92 months, which was significantly higher than that of the other groups.
  • CONCLUSION: Early diagnosis of primary small intestinal tumors is difficult and with a preoperative misdiagnosis rate of 43.0%.
  • Total intestinal barium swallowing, endoscopy and superior mesenteric arteriography are three critical examinations for diagnosis and location.
  • The primary small intestinal tumor should be resected as early as possible if no distant metastasis is detected.
  • [MeSH-major] Adenocarcinoma. Diagnostic Errors. Digestive System Surgical Procedures / methods. Duodenal Neoplasms
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Female. Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / secondary. Gastrointestinal Stromal Tumors / surgery. Humans. Ileal Neoplasms / diagnosis. Ileal Neoplasms / pathology. Ileal Neoplasms / surgery. Jejunal Neoplasms / diagnosis. Jejunal Neoplasms / pathology. Jejunal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / surgery. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396694.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Salem PA, Estephan FF: Immunoproliferative small intestinal disease: current concepts. Cancer J; 2005 Sep-Oct;11(5):374-82
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease: current concepts.
  • Immunoproliferative small intestinal disease is a distinctive lymphoproliferative disorder.
  • Among these disorders, it is the only disease associated with a specific and characteristic abnormal protein, and also an identifiable, at least in some patients, early phase with a benign-looking histo-pathologic expression.
  • In contrast to primary nonimmunoproliferative small intestinal lymphomas, in which the pathology in the intestine is usually focal and involving specific segments of the intestine and leaving the segments between the involved areas free of disease, the pathology in immunoproliferative small intestinal disease is diffuse, with a mucosal cellular infiltrate involving large segments of the intestine and sometimes the entire length of the intestine, thus producing malabsorption.
  • Additional research is indicated not only to understand this specific lymphoproliferative disorder but also to understand lymphomas in general.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease
  • [MeSH-minor] Humans. Laparotomy. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259867.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


12. Nawgiri RS, Nagle JA, Wilbur DC, Pitman MB: Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium. Diagn Cytopathol; 2007 May;35(5):300-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology and B72.3 labeling of benign and malignant ductal epithelium in pancreatic lesions compared to gastrointestinal epithelium.
  • We studied the cytomorphology and B72.3 immunoreactivity of lesional epithelium of benign and malignant ductal lesions of the pancreas and compared the findings to our previously established template of GIC.
  • Air-dried smears, fixed smears, and ThinPrep (TP) specimens were obtained using a cytobrush, directly from benign and malignant ductal lesions of 18 Whipple specimens, to ensure purity of the epithelium studied.
  • Epithelium of ductal carcinoma was distinguished from benign ductal epithelium in chronic pancreatitis and GIC primarily by crowded architecture and atypical cellular features, including high nuclear-to-cytoplasmic ratio, irregular nuclei, nucleoli, and vacuolated cytoplasm.
  • Benign ductal and GIC epithelium were only distinguished by architecture (goblet cells and brush borders), but not consistently, especially gastric epithelium that lacked these features.
  • B72.3 shows promise in the differentiation between GIC and benign and malignant ductal epithelium, with no staining supporting benign ductal cells, fine punctate perinuclear staining correlating with GIC, and strong cytoplasmic staining supporting malignancy.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Carcinoma, Pancreatic Ductal / pathology. Gastric Mucosa / pathology. Intestinal Mucosa / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427224.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / B72.3 antibody; 0 / Biomarkers
  •  go-up   go-down


13. Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, Yasunaga M, Kobayashi H, Wake N, Tsuneyoshi M: Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type. Oncol Rep; 2010 Dec;24(6):1569-76
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic and stromal expression of laminin γ 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinal type.
  • Ovarian mucinous neoplasms of gastro-intestinal type (GI-type) are known to be a heterogeneous tumor composed of benign, borderline and non-invasive and invasive malignant lesions.
  • The presence of infiltrative invasion is also known to be an important prognostic factor of this neoplasm.
  • Laminin γ 2 chain, known to stimulate tumor cell invasion and migration, has not been sufficiently investigated in ovarian mucinous neoplasms.
  • The purpose of this study was thus to clarify the role of laminin γ 2 in ovarian mucinous neoplasms of GI-type.
  • We selected each morphological phase of tumor development from 61 cases of mucinous neoplasms of the GI-type: 55 adenoma lesions, 60 borderline lesions, 20 microinvasive lesions, 17 intraepithelial carcinoma lesions, 38 expansile invasive carcinoma lesions, 19 infiltrative invasive carcinoma lesions and 5 mural nodules lesions; and evaluated the localization of laminin γ 2 in the lesions using immunohistochemical method.
  • The infiltrative invasion of GI-type ovarian mucinous neoplasms may be promoted by cytoplasmic and/or stromal expression of laminin γ 2 chain.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastrointestinal Neoplasms / pathology. Laminin / metabolism. Neoplasm Staging / methods. Ovarian Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cohort Studies. Cytoplasm / metabolism. Disease Progression. Female. Humans. Models, Biological. Neoplasm Invasiveness. Prognosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042753.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


14. Coco C, Rizzo G, Manno A, Mattana C, Verbo A: Surgical treatment of small bowel neoplasms. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):327-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of small bowel neoplasms.
  • Small intestinal neoplasms are uncommon cancers.
  • Benign small intestinal tumors (e.g., leiomyoma, lipoma, hamartoma, or desmoid tumor) usually are asymptomatic but may present with complications.
  • Primary malignancies of the small intestine, including adenocarcinoma, leiomyosarcoma, carcinoid, and lymphoma, are often symptomatic and may present with intestinal obstruction, jaundice, bleeding, or pain.
  • Metastatic neoplasms may involve the small intestine via contiguous spread, peritoneal metastases or hematogenous metastases.
  • Because the small intestine is relatively inaccessible to routine endoscopy, diagnosis of small intestinal neoplasms is often delayed for months after onset of symptoms.
  • During last years the increase of small bowel endoscopy and other diagnostic tools allow earlier non-operative diagnosis.
  • Even though radical resection of small bowel cancer plays an important role, the 5 yr overall survival remains low.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Intestine, Small / surgery
  • [MeSH-minor] Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Laparoscopy. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496543.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 51
  •  go-up   go-down


15. Majeski J: Endoscopic capsule retention in an intestinal anastomosis. Int Surg; 2009 Jul-Sep;94(3):254-7
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic capsule retention in an intestinal anastomosis.
  • CE has become a first line method of evaluating the small intestine for suspected abnormalities and disease.
  • Contraindications to CE include the presence of intestinal obstruction, fistulas, or structures.
  • Capsule retention has been reported in patients with a strictured or stenotic area of intestine caused by occult neoplasm, nonsteroidal anti-inflammatory drugs, Crohn's disease, radiation enteritis, or previous abdominal surgery.
  • Safe and effective use of CE has been reported in the evaluation of patients who have previously undergone surgical resection of the small intestine for benign or malignant disease.
  • This case report reviews the utilization and subsequent retention of an endoscopic capsule in a symptomatic patient who had a previous small bowel resection caused by the sequelae of radiation therapy to the abdomen and pelvis for endometrial cancer.
  • The resected segment of small intestine contained the endoscopic capsule, previous intestinal anastomosis, recurrent bowel strictures secondary to radiation enteritis, and a chronic ulcerated intestinal lumen caused by the retained endoscopic capsule.
  • This case report shows that use of CE cannot always be considered safe in patients who have had a previous surgical intestinal anastomosis.
  • CE should not be used in patients who have had a previous small bowel resection and anastomosis for symptomatic intestinal structures that developed because of radiation enteritis.
  • [MeSH-major] Capsule Endoscopy / adverse effects. Endometrial Neoplasms / surgery. Foreign Bodies / complications. Foreign Bodies / surgery. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Intestine, Small / surgery

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187521.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA: Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer; 2009 Jun;45(9):1654-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.
  • Therefore, we investigated CD74 gene expression in intestinal adenomas in Apc(Min/+) mice and humans.
  • CD74 mRNA (p31 and p41 splice variants) and immunoreactive CD74 protein levels were significantly lower in small intestinal and colonic Apc(Min/+) mouse adenomas compared with histologically normal mucosa.
  • Down-regulation of CD74 during Apc(Min/+) mouse intestinal tumorigenesis does not model increased CD74 expression at the early, benign stages of human colorectal carcinogenesis.
  • [MeSH-major] Adenoma / immunology. Antigens, Differentiation, B-Lymphocyte / metabolism. Antigens, Neoplasm / metabolism. Colorectal Neoplasms / immunology. Histocompatibility Antigens Class II / metabolism
  • [MeSH-minor] Animals. Down-Regulation / immunology. Gene Expression Regulation, Neoplastic / immunology. Humans. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Mice. Mice, Inbred C57BL. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269807.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G116/146; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class II; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / invariant chain; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


17. Safioleas MC, Constantinos K, Michael S, Konstantinos G, Constantinos S, Alkiviadis K: Benign multicystic peritoneal mesothelioma: a case report and review of the literature. World J Gastroenterol; 2006 Sep 21;12(35):5739-42
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign multicystic peritoneal mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign multicystic peritoneal mesothelioma: a case report and review of the literature.
  • Benign multicystic peritoneal mesothelioma (BMPM) is a rare tumor that occurs mainly in women in their reproductive age.
  • Upright plain abdominal film revealed small bowel loops with air-fluid levels.
  • She was diagnosed having an incarcerated incisional hernia that resulted in intestinal obstruction.
  • The patient underwent surgery during which a cystic mass of the right ovary measuring 6 cm multiply 5 cm multiply 4 cm, four small cysts of the small bowel (1 cm in diameter) and a cyst at the retroperitoneum measuring 11 cm multiply 10 cm multiply 3 cm were found.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Mesothelioma, Cystic / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasms / diagnosis. Neoplasms / etiology. Neoplasms / pathology. Neoplasms / surgery

  • Genetic Alliance. consumer health - Benign multicystic peritoneal mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2000 May;82(3):196-7 [10858684.001]
  • [Cites] Mayo Clin Proc. 1982 Oct;57(10):634-8 [7121070.001]
  • [Cites] Pathol Annu. 1989;24 Pt 2:1-21 [2671878.001]
  • [Cites] J Urol. 1990 Feb;143(2):347-8 [2299728.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):375-8 [2181883.001]
  • [Cites] Am J Clin Pathol. 1990 Dec;94(6):758-61 [1700878.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):169-71 [1734224.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Dec;71(8):642-4 [1336927.001]
  • [Cites] J Clin Pathol. 1993 Sep;46(9):867-8 [8227441.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2B):715-20 [7516639.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):377-80 [8088617.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):901-3 [7724156.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):157-60 [7773468.001]
  • [Cites] Histopathology. 1995 Nov;27(5):479-81 [8575742.001]
  • [Cites] Histopathology. 1996 Oct;29(4):375-7 [8910046.001]
  • [Cites] J Clin Pathol. 1986 Apr;39(4):440-5 [2422221.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):844-54 [3789251.001]
  • [Cites] Histopathology. 1988 May;12(5):555-8 [3294158.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] Radiology. 1989 Feb;170(2):333-7 [2643136.001]
  • [Cites] Diagn Cytopathol. 1989;5(1):14-21 [2656144.001]
  • [Cites] Cancer J Sci Am. 1997 May-Jun;3(3):174-9 [9161783.001]
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):131-3 [9698490.001]
  • [Cites] Abdom Imaging. 1998 Sep-Oct;23(5):502-4 [9841063.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):166-75 [9989843.001]
  • [Cites] BJU Int. 1999 Sep;84(4):533-4 [10468779.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):582-90 [10493628.001]
  • [Cites] Magy Seb. 2005 Feb;58(1):35-7 [16018599.001]
  • [Cites] Pol J Pathol. 2005;56(2):81-7 [16092670.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1101-7 [16343188.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jul;13(3):273-8 [7928060.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1205-7 [7528798.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):399-400 [11328842.001]
  • [Cites] Cesk Patol. 2000 Oct;36(4):160-2 [11378909.001]
  • [Cites] ANZ J Surg. 2001 Oct;71(10):615-8 [11552941.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):192-5 [11884057.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):220 [11961660.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1523-7 [12409730.001]
  • [Cites] Z Gastroenterol. 2003 Apr;41(4):329-32 [12695939.001]
  • [Cites] Tumori. 2003 Jan-Feb;89(1):31-5 [12729358.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):517-8 [12789944.001]
  • [Cites] J Obstet Gynaecol. 2003 Sep;23(5):576 [12963534.001]
  • [Cites] Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S41-3 [14727459.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Cancer. 1980 May 1;45(9):2395-9 [7379036.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • (PMID = 17007034.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC4088182
  •  go-up   go-down


18. Eren S: A sporadic abdominal desmoid tumour case presenting with intermittent intestinal obstruction. Eur J Pediatr Surg; 2005 Jun;15(3):196-9
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sporadic abdominal desmoid tumour case presenting with intermittent intestinal obstruction.
  • Desmoid tumours, also known as aggressive fibromatoses, are rare lesions having intermediate biological behaviour between benign fibrous lesions and fibrosarcomas.
  • Intestinal obstruction and invasion of colon wall had occurred.
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Intestinal Obstruction / complications. Mesentery. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Child. Colon / pathology. Humans. Male. Nausea / etiology. Neoplasm Invasiveness. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999314.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Seo GJ, Sohn DK, Han KS, Hong CW, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH: Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps. World J Gastroenterol; 2010 Jun 14;16(22):2806-11
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps.
  • AIM: To evaluate the safety and outcomes of endoscopic piecemeal mucosal resection (EPMR) for large sessile colorectal polyps.
  • METHODS: The patients enrolled in this study were 47 patients with 50 large sessile polyps (diameter, 2 cm or greater) who underwent EPMR using a submucosal saline injection technique between December 2002 and October 2005.
  • Of 50 polyps identified, 34 (68%) were benign and 16 (32%) were malignant.
  • The recurrence rate after EPMR was 3.1% for benign polyps and 33.3% for malignant polyps (P < 0.05).
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):697-700 [10840302.001]
  • [Cites] J Gastroenterol Hepatol. 2010 Jan;25(1):84-9 [19793173.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):212-8 [12584639.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Gut. 2004 Apr;53(4):568-72 [15016753.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Am J Gastroenterol. 1977 May;67(5):430-8 [900105.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):128-32 [2032596.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):303-9 [1607080.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):840-4 [17253129.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):229-51, ix [18313548.001]
  • [Cites] World J Gastroenterol. 2008 Apr 21;14(15):2364-9 [18416463.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4289-95 [18666315.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):615 [18760188.001]
  • [Cites] J Gastroenterol. 2008;43(9):641-51 [18807125.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):343-52 [19517168.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • (PMID = 20533602.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2883138
  •  go-up   go-down


20. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • Immunohistochemically, although only a small part of the epithelium with intestinal metaplasia in 2 of 4 cases with adenomyomatosis showed Reg IV expression, Reg IV was negative in all cases with normal gallbladder (n = 15) and cholelithiasis (n = 13).
  • Expression was more frequently observed in well to moderately differentiated than in poorly differentiated adenocarcinomas and significantly correlated with expression of caudal-related homeobox transcription factor (a candidate for involvement in the induction of intestinal metaplasia).
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • The serum levels of Reg IV decreased after surgical resection of the tumors.
  • These results suggest that Reg IV is involved in gallbladder carcinoma carcinogenesis through intestinal metaplasia and is associated with relatively favorable prognosis in patients after surgery.
  • The serum level of Reg IV may be of use or indicative of neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Gene Expression. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


21. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Guglielminetti D, Guerra E, Minguzzi MT, Zanzi F, Poddie DB: [Retractile mesenteritis: case report]. G Chir; 2009 Jan-Feb;30(1-2):30-2
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mesenteritis is a benign disease and sometimes it is related to urogenital neoplasm.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / therapy. Adenocarcinoma, Clear Cell / surgery. Anti-Inflammatory Agents / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Fluorouracil / therapeutic use. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Kidney Neoplasms / surgery. Male. Methylprednisolone / therapeutic use. Middle Aged. Neoadjuvant Therapy. Neoplasms, Multiple Primary / therapy. Panniculitis / diagnosis. Panniculitis / etiology. Panniculitis / therapy. Parenteral Nutrition. Rectal Neoplasms / complications. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19272229.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


23. Serra S, Asa SL, Bamberger AM, Wagener C, Chetty R: CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol; 2009 Jul;17(4):286-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM1 expression in pancreatic endocrine tumors.
  • The aim of this study was to examine the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in pancreatic endocrine tumors (PETs) and to correlate it with clinicopathologic parameters.
  • Sixty-nine PETs were examined for tumor size, necrosis, local peripancreatic invasion and lymphovascular invasion, lymph node, and liver metastasis.
  • The mitotic count, expressed per 10 high-power fields (HPF) and MIB1 index were assessed and tumors were classified according to the World Health Organization classification.
  • Twenty-nine tumors were from males and 40 from females, age range: 23 to 80 years (mean 52.4 y), tumor size ranged from 0.8 to 11 cm (mean 3.5 cm), 8 patients had multiple endocrine neoplasia 1 syndrome, and 1 had von Hippel-Lindau disease.
  • Twenty tumors demonstrated local invasion, 32 had lymphovascular invasion, 16 had lymph node metastasis, and 10 had liver metastasis.
  • In addition, 80% of tumors >or=2 cm in diameter were CEACAM positive (P<0.05).
  • CEACAM1-positive tumors were more frequently insulin negative (9 of 10 cases) (P=0.005) and vasoactive intestinal peptide-positive PETs were all CEACAM1 immunopositive (7 of 7 cases) (P=0.005).
  • Benign tumors and PETs of uncertain malignant behavior were more frequently CEACAM1-negative and low-grade malignant cases were CEACAM1 positive (27 of 29 cases) (P=0.001).
  • In addition, CEACAM1-positive tumors were statistically correlated with cytokeratin 19-positive tumors (P<0.05).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349857.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins
  •  go-up   go-down


24. Lasota J, vel Dobosz AJ, Wasag B, Wozniak A, Kraszewska E, Michej W, Ptaszynski K, Rutkowski P, Sarlomo-Rikala M, Steigen SE, Schneider-Stock R, Stachura J, Chosia M, Ogun G, Ruka W, Siedlecki JA, Miettinen M: Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest; 2007 Oct;87(10):1029-41
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of gastrointestinal tract.
  • GISTs range from benign indolent neoplasms to highly malignant sarcomas.
  • In this study, we report 36 GIST patients whose tumors had homozygous KIT exon 11 mutations detected by direct sequencing of PCR products.
  • Loss of heterozygosity in KIT locus and other chromosome 4 loci were documented in majority of these tumors.
  • Homozygous KIT exon 11 mutations were found in 33 primary tumors and 7 metastatic lesions.
  • In two cases, shift from heterozygosity to homozygosity was documented during tumor progression being present in metastases, but not in primary tumors.
  • Among primary GISTs, there were 16 gastric, 18 intestinal and 2 from unknown locations.
  • An average primary tumor size was 12 cm and average mitotic activity 32/50 HPFs.
  • Out of 32 tumors 29 (90.6%) with complete clinicopathologic data were diagnosed as sarcomas with more than 50% risk of metastatic disease, and 26 of 29 patients with follow-up had metastases or died of disease.
  • [MeSH-major] Gastrointestinal Stromal Tumors / genetics. Loss of Heterozygosity. Neoplasm Metastasis / genetics. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lab Invest. 2008 May;88(5):456-7 [18432212.001]
  • (PMID = 17632543.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


25. Mann CM, Bramhall SR, Buckels JA, Taniere P: An unusual case of duodenal obstruction-gangliocytic paraganglioma. J Hepatobiliary Pancreat Surg; 2009;16(4):562-5
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliocytic paragangliomas are rare tumors located in the gastrointestinal tract that are considered to be benign.
  • Intraoperatively, the patient was found to have local tumor extension and regional lymph node invasion, and so she underwent a pylorus-preserving pancreaticoduodenectomy, with local lymph node clearance.
  • [MeSH-major] Duodenal Neoplasms / complications. Intestinal Obstruction / etiology. Paraganglioma / complications
  • [MeSH-minor] Adolescent. Endoscopy, Digestive System. Female. Humans. Lymph Nodes / pathology. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517054.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


28. Papalambros A, Petrou A, Brennan N, Bramis K, Felekouras E, Papalambros E: GIST suture-line recurrence at a gastrojejunal anastomosis 8 years after gastrectomy: can GIST ever be described as truly benign? A case report. World J Surg Oncol; 2010;8:90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GIST suture-line recurrence at a gastrojejunal anastomosis 8 years after gastrectomy: can GIST ever be described as truly benign? A case report.
  • We present the case of a 71 year old man with recurrence of a Gastro Intestinal Stromal Tumour (GIST) at the gastrojejunal anastomosis eight years following partial gastrectomy for a very small primary gastric GIST.
  • The histopathology was in keeping with a diagnosis of a gastric GIST with a <2 cm tumour, with <5 mitosis per 50/HPF, no signs of necrosis and invasion limited to the mucosa.
  • He subsequently underwent completion gastrectomy and the histology revealed a 0.8 cm GIST tumour composed of spindle cells with <5 mitosis per 50/HPF, tumor invasion into the submucosa and positive expression of c-kit and SMA.
  • The literature suggests that tumour size, mitotic rate and tumour site are the most important predictive factors of recurrence.
  • Additional features such as the presence of necrosis, local tumour invasion and positive resection margins, can also influence recurrence rates.
  • In this case the lesion was a gastric GIST, very small (<2 cm), had low proliferation rate (<5 mitosis/HPF), lacked necrosis and was limited to the mucosa.
  • This case highlights how even the most innocent GISTs can never be described as truly benign.
  • [MeSH-major] Gastrectomy / methods. Gastrointestinal Stromal Tumors / surgery. Jejunum / surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Stomach / surgery. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4 [20457867.001]
  • [Cites] Oncology. 2010;78(2):130-40 [20389135.001]
  • [Cites] Hepatogastroenterology. 2010 Jan-Feb;57(97):95-7 [20422880.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):111-27 [20165865.001]
  • [Cites] Chin Med J (Engl). 2010 Jan 20;123(2):131-6 [20137358.001]
  • [Cites] J Egypt Natl Canc Inst. 2008 Mar;20(1):80-9 [19847285.001]
  • [Cites] APMIS. 2009 Feb;117(2):73-86 [19239429.001]
  • [Cites] J Nippon Med Sch. 2008 Oct;75(5):306-11 [19023173.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1553-9 [18724245.001]
  • [Cites] Pol Arch Med Wewn. 2008 Apr;118(4):216-21 [18575421.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):289-93 [15900576.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Br J Surg. 2010 Dec;97(12):1854-9 [20730857.001]
  • (PMID = 20946677.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2965163
  •  go-up   go-down


29. Khoury T, Chadha K, Javle M, Donohue K, Levea C, Iyer R, Okada H, Nagase H, Tan D: Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer; 2005;35(3):171-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma.
  • BACKGROUND: Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play a role in mucosal restitution, angiogenesis, apoptosis, and tumor progression.
  • Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC.
  • Tumor/ normal tissue interface was assessable in 21 cases; 11 cases expressed TFF-3 at the interface.
  • There was a strong correlation between tumor grade and TFF-3 expression, wherein poorly differentiated tumors had moderate/strong TFF-3 expression (p = 0.008).
  • CONCLUSION: TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110118.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 146046-78-8 / trefoil factor
  •  go-up   go-down


30. Rettenmaier M, Epstein HD, Abaid LN, Bechtol KA, Goldstein BH: Leiomyosarcoma with synchronous clear cell ovarian carcinoma. Onkologie; 2010;33(12):695-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine leiomyomas are typically considered benign lesions.
  • Following surgery, the patient was diagnosed with a 16 cm ovarian mass and a synchronous leiomyosarcoma; the latter neoplasm appeared to originate from a previously resected uterine leiomyoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Leiomyoma / surgery. Leiomyosarcoma / diagnosis. Leiomyosarcoma / surgery. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Postoperative Complications / diagnosis. Uterine Neoplasms / diagnosis. Uterine Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cell Transformation, Neoplastic / pathology. Chemotherapy, Adjuvant. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Female. Humans. Hysterectomy. Intestinal Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestinal Neoplasms / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Omentum / pathology. Omentum / surgery. Ovariectomy. Salpingectomy. Uterus / pathology


31. Jang JY, Park YC, Song YS, Lee SE, Hwang DW, Lim CS, Lee HE, Kim WH, Kim SW: Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas. J Hepatobiliary Pancreat Surg; 2009;16(5):668-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
  • PURPOSE: The purpose of this study was to document the biological changes during the progression of intraductal papillary mucinous neoplasm of the pancreas (IPMN) and to identify biological markers capable of differentiating benign and malignant IPMN.
  • The paraffin-embedded tumors from 27 with benign IPMNs and from 14 with IPMCs were subjected to immunohistochemical staining and DNA extraction.
  • RESULTS: K-ras mutations at codon 12 and 13 were detected in 13 of 37 (38.2%) of the IPMNs: in 5 of 24 (20.8%) of benign IPMNs, and in 8 of 13 (61.5%) of malignant IPMNs (p = 0.028).
  • S100A4 was expressed in 2 (7.4%) of 27 benign IPMNs, and 6 (42.9%) of 14 malignant IPMNs (p = 0.007).
  • MUC2 was expressed in 2 (7.4%) benign IPMNs, and in 9 (64.3%) malignant IPMNs (p < 0.001).
  • CONCLUSION: K-ras mutation and the expression of S100A4 and MUC2 (especially in intestinal subtype) were found to be related to malignancy in IPMN, and may be useful for the diagnosis and for assessing the biological behavior of IPMN.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Pancreatic Ductal / genetics. Mucin-2 / genetics. Pancreatic Neoplasms / genetics. S100 Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Genes, ras. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Neoplasm Staging. Polymerase Chain Reaction. Probability. Prognosis. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412570.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-2; 0 / S100 Proteins
  •  go-up   go-down


32. Vidal-González P, Cervantes-Castro J, Rojas-Reyna GA, Ramírez-Cerda C, Kunz-Martinez W, Toiber-Levy M: [Sclerosing mesenteritis. Presentation of three cases and review of the literature]. Cir Cir; 2008 Jul-Aug;76(4):343-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing mesenteritis or panniculitis is a rare condition characterized by inflammation of the mesentery ranging from an acute to a chronic fibrotic process that can resemble an intestinal malignant neoplasm even though it is benign.
  • Its natural history is benign and in most cases is self-limited.
  • Surgery is reserved only for those cases where there is intestinal obstruction.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Cholecystectomy. Cholecystitis / etiology. Cholecystitis / surgery. Colchicine / therapeutic use. Colectomy. Combined Modality Therapy. Diverticulosis, Colonic / surgery. Duodenal Diseases / etiology. Duodenal Diseases / surgery. Gastric Bypass / adverse effects. Gastritis / etiology. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Laparotomy. Male. Methylprednisolone / therapeutic use. Middle Aged. Prognosis. Reoperation. Tissue Adhesions / complications. Tissue Adhesions / surgery

  • Genetic Alliance. consumer health - Sclerosing mesenteritis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778547.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; SML2Y3J35T / Colchicine; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 22
  •  go-up   go-down


33. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • It is generally small, multifocal and located in the gastric fundus, has no tendency for vascular invasion and is associated with a benign course.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


34. De Padua M, Gupta N, Broor SL, Govil D: Duodenal angiomyolipoma: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):568-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma is a benign neoplasm, the most common site being the kidney.
  • [MeSH-major] Angiomyolipoma / diagnosis. Duodenum / pathology. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):859 [21045449.001]
  • (PMID = 17883138.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Ishida M, Egawa S, Aoki T, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Sunamura M, Unno M, Moriya T, Horii A, Furukawa T: Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas; 2007 Nov;35(4):348-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
  • OBJECTIVES: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas encompasses a spectrum of neoplasms with both morphological and immunohistochemical variations of mucin glycoproteins.
  • Recently, a consensus nomenclature and criteria were histologically defined for classifying these variants of IPMNs into gastric, intestinal, pancreatobiliary, and oncocytic types.
  • RESULTS: Our series included 27 gastric-, 29 intestinal-, 4 pancreatobiliary-, and 1 oncocytic-type IPMNs.
  • Characteristically, the gastric-type IPMNs were likely to be diagnosed as benign, to be confined to branch ducts, and to have fair prognoses.
  • On the other hand, the intestinal-type IPMNs were likely to be diagnosed as malignant, occupy the main duct, and have poor prognoses.
  • Because of the small number of pancreatobiliary-type IPMNs and only 1 case of oncocytic-type IPMN, we were unable to determine any of their clinicopathological characteristics in our series.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mucin 5AC. Mucin-1 / analysis. Mucin-2. Mucins / analysis. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090241.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


36. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM: A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma (Larchmt); 2007 Feb;26(1):22-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunostaining of MMP-7 in normal tissues or benign tumors of intestinal, breast, and prostatic origin indicates that this protein is normally localized luminally in glandular epithelium.
  • The localization pattern would suggest that in normal or early stage tumors, MMP-7 is most likely not directly involved in extracellular matrix degradation.
  • In contrast, advanced colon tumors show MMP-7 in invading cells at the advancing edge of the tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1441-7 [10607586.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Science. 1999 Oct 1;286(5437):113-7 [10506557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Prostate. 1996 Sep;29(3):159-68 [8827084.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Feb;28(2):123-36 [8729000.001]
  • [Cites] Protein Expr Purif. 1994 Feb;5(1):27-36 [8167471.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):119-35 [15000153.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • (PMID = 17316082.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA60867; United States / NCI NIH HHS / CA / R01 CA84360; United States / NIAMS NIH HHS / AR / AR36457; United States / NCI NIH HHS / CA / R01 CA084360; United States / NIAMS NIH HHS / AR / P30 AR48311; United States / NIAMS NIH HHS / AR / P30 AR048311; United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enzyme Precursors; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ NIHMS403810; NLM/ PMC3838102
  •  go-up   go-down


37. Yimyaem P, Saranrittichai S, Sinawat P, Dhiensiri T: Inflammatory myofibroblastic tumor of the small intestine: a case report of a 2 month-old infant. J Med Assoc Thai; 2009 Jan;92(1):114-9
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the small intestine: a case report of a 2 month-old infant.
  • Benign intestinal tumors are rare in children; however, the authors describe an inflammatory myofibroblastic tumor (IMT) of the terminal ileum in a 2-month-old infant who presented with an intestinal obstruction.
  • A review of the literature for this rare condition was done to delineate the natural history of this tumor and to do a histological confirmation of its benign nature.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Ileal Diseases / pathology. Intestinal Obstruction / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260252.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


38. Inbar R, Greenberg R, Nir S, Shmueli E, Scornick Y, Avital S: [Three hundred laparoscopic colorectal operations--safety, levels of difficulty and survival]. Harefuah; 2010 Aug;149(8):498-502, 552, 551
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for surgery included cancer (58%), benign polyps (16%), Crohn's disease (6%), diverticular disease (10%) and others (10%).
  • [MeSH-major] Colorectal Neoplasms / surgery. Intestinal Diseases / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Elective Surgical Procedures / adverse effects. Elective Surgical Procedures / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Prospective Studies. Reoperation. Surgical Wound Infection / epidemiology. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21341427.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


39. Adam N, Lim SS, Ananda V, Chan SP: VIPoma syndrome: challenges in management. Singapore Med J; 2010 Jul;51(7):e129-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour.
  • It may be curative in forty percent of patients with benign and non-metastatic disease.
  • Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects.
  • [MeSH-major] Liver Neoplasms / secondary. Palliative Care. Pancreatic Neoplasms / pathology. Vipoma / secondary
  • [MeSH-minor] Catheter Ablation / methods. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Octreotide / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - VIPoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730389.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] RWM8CCW8GP / Octreotide
  •  go-up   go-down


40. Willis S, Schumpelick V: [Open colon surgery]. Chirurg; 2005 Nov;76(11):1073-81
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical aim is resection of the affected intestinal region and the according lymph drainage region.
  • In case of benign underlying disease, the operational method depends largely on the extent to which the intestine is affected and can include anything from simple colotomy and polyp removal to colectomy for toxic megacolon.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Lymph Node Excision / methods. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Colon / pathology. Colonic Polyps / mortality. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Surgical Staplers. Surgical Wound Dehiscence / mortality. Survival Analysis. Suture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1988 May;75(5):409-15 [3292002.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1071-8 [15316639.001]
  • (PMID = 16240155.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • The microscopic features were similar to those of GCTs found elsewhere, but many of the neoplasms differed by displaying nuclear pleomorphism (8/20, 40%), lymphoid cuffs (9/20, 45%), and focal calcification (7/20, 35%).
  • On immunochemistry, 18 of the neoplasms were stained for S-100 and all cases showed positive staining.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


46. Kars M, Roelfsema F, Romijn JA, Pereira AM: Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol; 2006 Oct;155(4):523-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas.
  • In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas.
  • In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor.
  • For pituitary tumors that exhibit high mitotic activity, increased Ki-67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990651.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Pyrrolidines; 107188-87-4 / epidepride; 9002-62-4 / Prolactin
  • [Number-of-references] 47
  •  go-up   go-down


47. Ganai S, Kanumuri P, Rao RS, Alexander AI: Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. Ann Surg Oncol; 2006 Apr;13(4):547-56
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) allows for local excision of rectal neoplasms with greater exposure than transanal excision and less morbidity than transabdominal approaches.
  • RESULTS: The study comprises 107 patients presenting for TEM with benign disease and 32 patients with cancer.
  • Pathologic classification of the lesions after TEM was benign adenoma in 45%, adenoma with high-grade dysplasia (HGD) in 17%, cancer in 33%, and other in 4%.
  • Recurrence of cancers correlated with the depth of tumor invasion (P<.05).
  • Five-year neoplastic recurrence probabilities were 11% for benign adenomas, 35% for adenomas with HGD, and 20% for cancers (P=.31); invasive recurrence probabilities were 0% for benign adenomas, 15% for adenomas with HGD, and 13% for cancers (P<.05).
  • CONCLUSIONS: Close endoscopic follow-up is warranted after TEM for both benign and malignant disease, with special attention to lesions with HGD.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Colonoscopy. Intestinal Polyps / pathology. Intestinal Polyps / surgery. Microsurgery. Neoplasm Recurrence, Local. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514476.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


49. Van Weyenberg SJ, Meijerink MR, Jacobs MA, Van der Peet DL, Van Kuijk C, Mulder CJ, Van Waesberghe JH: MR enteroclysis in the diagnosis of small-bowel neoplasms. Radiology; 2010 Mar;254(3):765-73
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR enteroclysis in the diagnosis of small-bowel neoplasms.
  • PURPOSE: To evaluate the diagnostic accuracy and interobserver variance of magnetic resonance (MR) enteroclysis in the diagnosis of small-bowel neoplasms, with small-bowel endoscopy, surgery, histopathologic analysis, and follow-up serving as standards of reference, and to identify MR enteroclysis characteristics capable of enabling discrimination between benign and malignant small-bowel neoplasms.
  • Only studies explicitly performed to investigate or exclude the presence of small-bowel neoplasms were included.
  • Tumor characteristics were compared with the Student t test and the Fisher exact test.
  • RESULTS: Readers 1 and 2 interpreted 31 and 33 studies, respectively, as depicting a small-bowel neoplasm and 19 and 17 studies, respectively, as depicting small-bowel malignancy.
  • In 32 patients, the presence of small-bowel neoplasm was confirmed.
  • In 19 of these patients, the neoplasm was malignant.
  • Sensitivity and specificity in the diagnosis of small-bowel neoplasms was 0.91 and 0.95, respectively, for reader 1 and 0.94 and 0.97, respectively, for reader 2; the kappa value was 0.95.
  • CONCLUSION: Eighty-six of 91 studies were correctly interpreted, resulting in an overall diagnostic accuracy of 0.95 for MR enteroclysis in the detection of small-bowel neoplasms.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small. Magnetic Resonance Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2010
  • (PMID = 20177091.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


50. Hausbrandt PA, Leithner A, Beham A, Bodo K, Raith J, Windhager R: A rare case of infantile myofibromatosis and review of literature. J Pediatr Orthop B; 2010 Jan;19(1):122-6
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for infantile myofibromatosis .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infantile myofibromatosis is a rare benign tumor-disease (1/400,000).
  • Radiographic films and ultrasound examination presented a pretibial soft-tissue tumor mass with calcifications and two osteolytic lesions with a sclerotic rim.
  • Infantile myofibromatosis is a very rare benign tumor-disease.
  • However, a thorough examination has to be carried out to exclude lesion in other organs like gastro-intestinal or cardio-pulmonary nodular tumor masses.
  • [MeSH-major] Myofibromatosis / pathology. Soft Tissue Neoplasms / pathology. Tibia / pathology
  • [MeSH-minor] Calcinosis / pathology. Calcinosis / physiopathology. Diagnosis, Differential. Follow-Up Studies. Frozen Sections. Histiocytosis, Langerhans-Cell / diagnosis. Humans. Infant. Male. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Infantile myofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738495.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


51. Priego P, Lobo E, Alonso N, Gil Olarte MA, Pérez de Oteyza J, Fresneda V: Surgical treatment of esophageal leiomyoma: an analysis of our experience. Rev Esp Enferm Dig; 2006 May;98(5):350-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: leiomyoma is the most common benign esophageal neoplasm.
  • No death, intraoperative complication, or tumor relapse was described.
  • Only 2 patients had complications: post-surgical thoracic pain, and intestinal obstruction by adhesions 8 years after surgery.
  • [MeSH-major] Esophageal Neoplasms / surgery. Leiomyoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944995.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


52. Lee JH, Ross WA, Davila R, Chang G, Lin E, Dekovich A, Davila M: Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary cancer center. Dig Dis Sci; 2010 Dec;55(12):3530-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Self-expandable metal stents (SEMS) can be used to relieve benign and malignant colorectal obstruction.
  • [MeSH-major] Intestinal Obstruction / therapy. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon, Sigmoid / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Constriction, Pathologic. Female. Fluoroscopy. Foreign-Body Migration / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prosthesis Design. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721627.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Wrba F: [Gastrointestinal stomal tumours, morphology and molecular pathology]. Wien Med Wochenschr; 2009;159(15-16):383-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the digestive tract.
  • GIST are not regarded as benign tumours, and morphological risk assessment is generally recommended according to the NIH consensus adapted from Fletcher et al.
  • Other classifications (Miettinen and Lasota, Joensuu) considering the tumour site and tumour integrity as individual criterion may give different assessment results.
  • In doing so the use of a panel of antibodies is recommended helpful to cover all differential diagnostic relevant possibilities of mesenchymal neoplasms of the digestive tract.
  • [MeSH-major] Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Chloride Channels. DNA Mutational Analysis. Diagnosis, Differential. Gastric Mucosa / pathology. Gastrointestinal Tract / pathology. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Membrane Proteins / genetics. Mitotic Index. Neoplasm Proteins / genetics. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696981.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / ANO1 protein, human; 0 / Biomarkers, Tumor; 0 / Chloride Channels; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Number-of-references] 11
  •  go-up   go-down


54. Maconi G, Manes G, Porro GB: Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol; 2008 Feb 28;14(8):1149-55
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, the overall prevalence of these symptoms in dyspeptic patients is high, while the prevalence of gastro-intestinal cancer is very low.
  • Moreover, symptoms of early stage cancer may be indistinguishable from those of benign dyspepsia, while the presence of alarm symptoms may imply an advanced and often inoperable disease.
  • The features of dyspeptic and alarm symptoms may reflect the pathology of the tumour and be of prognostic value in suggesting site, stage and aggressiveness of cancer.
  • Dysphagia, weight loss and a palpable abdominal mass appear to be major independent prognostic factors in gastric cancer, while gastro-intestinal bleeding, vomiting and also duration of symptoms, do not seem to have a relevant prognostic impact on survival in gastric cancer.
  • [MeSH-major] Gastroenterology / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Endoscopy. Humans. Medical Oncology / methods. Neoplasm Staging / methods. Primary Health Care / methods. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Feb;85(2):255-60 [9501830.001]
  • [Cites] Gut. 1998 Jun;42(6):814-22 [9691920.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):503-9 [9713300.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1345-9 [16292088.001]
  • [Cites] Scand J Gastroenterol. 2005 Nov;40(11):1351-7 [16334445.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):53-6 [2302514.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2A):411-6 [2346315.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):722-9 [1985765.001]
  • [Cites] Scand J Gastroenterol. 1991 Jun;26(6):611-9 [1713708.001]
  • [Cites] Br J Surg. 1992 Apr;79(4):293-9 [1576492.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):355-7 [1427583.001]
  • [Cites] Cancer. 1993 May 15;71(10):2918-25 [8490819.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):475-8 [8495315.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1378-86 [8224642.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] Am Surg. 1993 Dec;59(12):850-4 [8256942.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):381-8; discussion 388-9 [7512326.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):496-500 [7676690.001]
  • [Cites] Postgrad Med J. 2006 Jan;82(963):52-4 [16397081.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):843-50 [16614885.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):697-708 [16997154.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1725-8 [17024539.001]
  • [Cites] Acta Oncol. 2007;46(3):308-15 [17450465.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Dec;12(12):1249-56 [9882034.001]
  • [Cites] Gut. 1999 Jul;45(1):15-9 [10369698.001]
  • [Cites] Postgrad Med J. 1999 Jan;75(879):22-6 [10396582.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1045-52 [15569106.001]
  • [Cites] Gut. 2005 Jan;54(1):40-5 [15591502.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):784-91 [15784019.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Apr 1;21(7):813-20 [15801916.001]
  • [Cites] Gastrointest Endosc. 2005 Jun;61(7):819-25 [15933682.001]
  • [Cites] Br J Surg. 2005 Jul;92(7):840-6 [15892157.001]
  • [Cites] Scand J Gastroenterol Suppl. 1999;231:3-8 [10565617.001]
  • [Cites] Gut. 2000 Jan;46(1):93-7 [10601062.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2000 Jan-Feb;24(1):7-14 [10638466.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14(4):413-20 [10759620.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001961 [10796841.001]
  • [Cites] Lancet. 2000 Aug 5;356(9228):455-60 [10981888.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):815-7 [11726874.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jan;16(1):105-10 [11856084.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Feb;16(2):167-80 [11860399.001]
  • [Cites] Scand J Gastroenterol. 2002 Sep;37(9):999-1007 [12374244.001]
  • [Cites] J Surg Oncol. 2002 Nov;81(3):118-24; discussion 124-5 [12407722.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2434-40 [12452375.001]
  • [Cites] Endoscopy. 2003 Jan;35(1):61-7 [12510228.001]
  • [Cites] Scand J Gastroenterol. 2003 Jan;38(1):109-13 [12613446.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jun 15;17(12):1481-91 [12823150.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1333-7 [14624157.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1249-55 [14750645.001]
  • [Cites] Gastric Cancer. 2004;7(1):9-16 [15052434.001]
  • [Cites] Aliment Pharmacol Ther. 2004 May 1;19(9):981-8 [15113364.001]
  • [Cites] Gastric Cancer. 2004;7(2):91-6 [15224195.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1067-75 [15480985.001]
  • [Cites] Am J Med. 1980 Oct;69(4):491-7 [7424938.001]
  • [Cites] J Clin Gastroenterol. 1981 Mar;3(1):17-20 [6268700.001]
  • [Cites] J Clin Oncol. 1984 Apr;2(4):305-10 [6707718.001]
  • [Cites] Cancer. 1985 Nov 15;56(10):2512-8 [4042074.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):811-7 [3802040.001]
  • [Cites] Ann Surg. 1989 Feb;209(2):162-6 [2644898.001]
  • [Cites] BMJ. 1997 Feb 15;314(7079):467-70 [9056794.001]
  • [Cites] Dig Dis Sci. 1997 Jun;42(6):1265-9 [9201093.001]
  • [Cites] Gut. 1997 Aug;41(2):142-50 [9301490.001]
  • [Cites] Nutrition. 1997 Oct;13(10):878-81 [9357024.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):579-81 [9496949.001]
  • (PMID = 18300338.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Number-of-references] 71
  • [Other-IDs] NLM/ PMC2690660
  •  go-up   go-down


55. Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Sakellariou S, Pantazopoulou A, Manika Z: Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of intraductal papillary mucinous neoplasms of the pancreas. A study of 8 cases. JOP; 2007;8(6):715-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of intraductal papillary mucinous neoplasms of the pancreas. A study of 8 cases.
  • CONTEXT: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized neoplasm of the pancreas, accounting for 5% of pancreatic neoplasms, it is considered difficult to diagnose by fine-needle aspiration (FNA) cytology.
  • In all cases, the hypoechoic mass had a distinctive distribution, involving the main pancreatic duct and/or the associated large branch ducts while intraductal nodules or multiple cysts were detected.
  • Two cases were diagnosed as benign IPMN and, in 3 cases, the biological behavior was not easy to determine by cytology alone (histologically diagnosed as borderline).
  • The histological diagnosis confirmed the FNA cytology diagnosis: 3 malignant IPMNs, 2 benign IPMNs and 3 borderline IPMNs.
  • Mucin 1 (MUC-1) was positive in 2 cases of malignant IPMN (histologically classified as null type ad intestinal type), mucin 2 (MUC-2) was positive in 3 cases (2 malignant both of the intestinal type, and 1 benign of the intestinal type I) and c-erbB2 was positive in 3 cases (2 benign - null and intestinal type - and 1 malignant null type).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993724.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mucins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


57. Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S: Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol; 2006 Feb;80(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional alterations that occur in UC-associated neoplasia in the progression from normal mucosa through dysplastic epithelium to invasive cancer have not been described.
  • We used Affymetrix U95Av2 microarrays to assess differential gene expression in the neoplastic progression of UC tissue from the colonic mucosa of individuals with benign UC, UC-dysplasia-associated lesions or masses, and UC adenocarcinoma.
  • There were, however, important differences that suggest that different molecular events may occur in the development of UC-associated neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Colitis, Ulcerative / metabolism. Colorectal Neoplasms / metabolism. Gene Expression Profiling. Intestinal Mucosa / metabolism. Precancerous Conditions / metabolism
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277983.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


58. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • Metastases to the small intestine are extremely rare, with only 1 case of metastatic spread to the duodenum reported in the literature.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


59. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Fukuta N, Kitano M, Maekawa K, Chikugo T, Kudo M: Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J Gastroenterol; 2005 Mar;40(3):247-55
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US.
  • The contrast-enhanced US with Levovist permits evaluation of the intratumoral vascularity of hepatic and pancreatic tumors and is useful for their differential diagnosis.
  • The purpose of the present study was to assess tumor vessels and the parenchymal flow of gastrointestinal stromal tumors (GISTs) by contrast-enhanced coded phase-inversion harmonic US and to evaluate whether vascularity is related to the malignant grade of the GISTs.
  • Tumors were observed in a real-time fashion of contrast-enhanced coded phase-inversion harmonic US after the injection of Levovist (400 mg/ml).
  • The vascular patterns were compared with tumor size, histological diagnosis, KIT mutations, and clinical findings such as metastasis.
  • RESULTS: The contrast-enhanced US images of the GISTs were classified into two types according to the blood flow area of the tumors as seen by real-time continuous imaging of the tumor vessels.
  • The image pattern "Poor" represented vessels flowing only in the peripheral part of the tumor, and "Rich" represented abundant vessels flowing from the periphery to the central part of the tumor.
  • Based on the final diagnosis, all tumors with "Poor" images were determined to be benign GISTs, and the rest tumors except one with "Rich" images were determined to be malignant GISTs.
  • [MeSH-major] Contrast Media. Gastrointestinal Stromal Tumors / blood supply. Neovascularization, Pathologic / ultrasonography. Polysaccharides
  • [MeSH-minor] Blood Flow Velocity / physiology. DNA, Neoplasm / genetics. Female. History, 17th Century. History, 18th Century. Humans. Infant, Newborn. Injections, Intravenous. Intestinal Mucosa / immunology. Intestinal Mucosa / pathology. Male. Microbubbles. Mutation. Neoplasm Staging / methods. Polymerase Chain Reaction. Proto-Oncogene Proteins c-kit / genetics. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Mar;40(3):320-1 [15830297.001]
  • (PMID = 15830283.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / DNA, Neoplasm; 0 / Polysaccharides; 127279-08-7 / SHU 508; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


61. Lee SH, Lee DS, You IY, Jeon WJ, Park SM, Youn SJ, Choi JW, Sung R: [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder]. Korean J Gastroenterol; 2010 Feb;55(2):119-26
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 1,847 cholecystectomized specimens, 63 specimens from 26 benign adenomas, 9 carcinomas in situ (CIS), and 28 invasive carcinomas were selected.
  • A pathologist reviewed all specimens and selected benign adenomas, CIS in the adenoma, and adenoma residue in invasive carcinomas.
  • Adenomas and adenoma-related lesions were classified according to morphology (tubular, tubulopapillary, and papillary) and the consisting epithelium (biliary, pyloric metaplasia, and intestinal metaplasia).
  • The age and the size of the benign adenomas and carcinomas in the adenoma were also compared.
  • All eight carcinomas arising in the adenoma were well-differentiated solitary tumors.
  • The diameters of the carcinomas in the adenoma were, on average, larger than that of the benign adenomas (1.8 cm vs. 0.9 cm, p=0.01).
  • The patients with carcinomas in the adenoma were, on average, older than those with benign adenomas, although the difference was insignificant (57 years vs. 47 years, p=0.09).
  • The morphology and consisting epithelium did not differ between the benign adenomas and carcinomas in the adenoma.
  • [MeSH-major] Adenoma / pathology. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma / surgery. Cell Transformation, Neoplastic. Cholecystectomy. Cystadenoma / epidemiology. Cystadenoma / pathology. Cystadenoma / surgery. Female. Gallstones / complications. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168058.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


62. Zuccarello C, Arena F, Fazzari C, Arena S, Nicòtina PA: Small bowel intussusception by local recurrence of an inflammatory myofibroblastic tumor: report of a case and review of the literature. Minerva Pediatr; 2006 Oct;58(5):495-8
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel intussusception by local recurrence of an inflammatory myofibroblastic tumor: report of a case and review of the literature.
  • Inflammatory myofibroblastic tumor (IMT) of the ileum is a rare, usually solitary lesion, that frequently presents small-intestinal intussusception and obstruction.
  • We describe an IMT of the ileum in a 4.5-year old child who presented a small bowel intussusception.
  • Three months after the operation, the patients were hospitalized with the symptoms of intestinal obstruction.
  • Along the previous suture line of anastomosis, a smooth polypoid tumor was evident.
  • Segmental resection of the ileum, including the tumor mass, was performed.
  • A review of the literature for this rare entity emphasizes the importance of immunohistochemical confirmation of its benign nature.
  • [MeSH-major] Ileal Diseases / etiology. Ileal Neoplasms / complications. Intussusception / etiology. Neoplasm Recurrence, Local / complications

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008862.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 17
  •  go-up   go-down


63. Sills ES, Doan TB, Mock RJ, Dixson GR, Rohlfing MB: Immunohistochemical localization patterns for vimentin and other intermediate filaments in calcified ovarian fibrothecoma. Diagn Pathol; 2006;1:28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopy identified three benign intestinal tubular adenomas.
  • Following laparoscopic excision of the pelvic tumor immunohistochemical analysis of the mass showed negative staining for keratin, S100 protein, inhibin, calretinin, melan A, smooth muscle actin, CD34, CD117, and desmin.
  • CONCLUSION: Ovarian fibrothecomas represent an ovarian stromal neoplasm developing in a wide spectrum of clinical settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Invest. 2000 Aug;47(3-4):148-51 [11019495.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Oct;30(5):368-71 [15327450.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2005 Mar;40(3):178-82 [15840313.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):83-92 [9422320.001]
  • [Cites] Arch Pathol Lab Med. 1989 Apr;113(4):372-6 [2539793.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1989 Nov;29(4):433-5 [2631678.001]
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):802-8 [7688213.001]
  • [Cites] Gynecol Obstet Invest. 1991;32(1):51-4 [1662660.001]
  • (PMID = 16965622.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1570478
  •  go-up   go-down


64. Ono S, Fujishiro M, Niimi K, Goto O, Kodashima S, Yamamichi N, Omata M: Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc; 2009 Nov;70(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms.
  • BACKGROUND: The long-term outcomes of endoscopic submucosal dissection (ESD) for superficial esophageal squamous cell neoplasms (ESCNs) have not been evaluated to date.
  • The enrolled patients were divided into 2 groups based on the lesion with the deepest invasion in each patient: group A, intraepithelial neoplasm or invasive carcinoma limited to the lamina propria mucosa and group B, invasive carcinoma deeper than the lamina propria mucosa.
  • During the median observation of 632 days (range 8-2358), 15 (18%) patients experienced benign esophageal stricture with dysphagia, which was successfully managed by balloon dilation for a median of 2 sessions (range 1-20).
  • LIMITATIONS: This was a retrospective study with a relatively short follow-up and a small number of patients from a single institution.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Dissection / methods. Endoscopy, Gastrointestinal / methods. Esophageal Neoplasms / surgery. Intestinal Mucosa / surgery
  • [MeSH-minor] Biopsy. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577748.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Yiğitler C, Ataç K, Yiğit T, Güleç B, Balkan M, Oner K: [A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma]. Ulus Travma Acil Cerrahi Derg; 2007 Jul;13(3):237-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma].
  • [Transliterated title] Erişkinde nadir bir intestinal intussusepsiyon ve kanama nedeni: Jejunal lipom.
  • Small bowel neoplasms are usually diagnosed when patients are referred with complications such as hemorrhage or obstruction.
  • Intestinal lipomas are the third most frequent benign tumors among all intestinal neoplasms and their definite diagnosis is usually obtained after histopathological examination of the resected specimen.
  • A 76 year-old male patient with partial intestinal obstruction and rectal bleeding at admittance was found to have an abdominal mass on ultrasound.
  • The diagnosis of lipoma was confirmed with histopathological examination of the mass removed by an elective intestinal resection.
  • This case was reported as the intestinal lipoma leading a jejunojejunal intussusception associated with bleeding, could be diagnosed preoperatively.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Intussusception / diagnosis. Intussusception / etiology. Jejunal Neoplasms / diagnosis. Lipoma / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978901.001).
  • [ISSN] 1306-696X
  • [Journal-full-title] Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES
  • [ISO-abbreviation] Ulus Travma Acil Cerrahi Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


66. Siddique K, Bhandari S, Basu S: Giant mesenteric lymphangioma: a rare cause of a life-threatening complication in an adult. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenteric cyst lymphangiomas (MCLs) are rare benign tumours of unknown aetiology seen mostly in children.
  • [MeSH-major] Intestinal Obstruction / etiology. Intestine, Small / surgery. Lymphangioma, Cystic / pathology. Mesenteric Cyst / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Abdomen, Acute / diagnosis. Abdomen, Acute / etiology. Anastomosis, Surgical. Critical Illness. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome. Vomiting / diagnosis. Vomiting / etiology. Young Adult

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1996 May;31(5):677-80 [8861480.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):383-6 [9412929.001]
  • [Cites] Int J Clin Pract. 2005 Aug;59(8):986-7 [16033626.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5084-6 [16124074.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Dec;20(12):1906-12 [16336452.001]
  • [Cites] Clin Radiol. 2001 Feb;56(2):156-8 [11222077.001]
  • [Cites] J Am Coll Surg. 2003 Apr;196(4):598-603 [12691938.001]
  • [Cites] Radiographics. 2003 Jul-Aug;23(4):847-51 [12853659.001]
  • [Cites] Saudi Med J. 2003 Oct;24(10):1130-2 [14578985.001]
  • [Cites] Br J Surg. 1989 May;76(5):485-9 [2660949.001]
  • [Cites] Surg Today. 1992;22(4):363-7 [1392347.001]
  • [Cites] Langenbecks Arch Chir. 1994;379(3):182-7 [8052061.001]
  • [Cites] Chirurg. 1995 Mar;66(3):229-31 [7750397.001]
  • (PMID = 22778193.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029268
  •  go-up   go-down


67. Wierzbicki PM, Adrych K, Kartanowicz D, Dobrowolski S, Stanislawowski M, Chybicki J, Godlewski J, Korybalski B, Smoczynski M, Kmiec Z: Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J Physiol Pharmacol; 2009 Oct;60 Suppl 4:63-70
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate loss of heterozygosity (LOH) at FRA3B, expression of FHIT gene at the mRNA and protein levels in sporadic colorectal carcinoma (CRC) and benign colon adenoma.
  • MATERIALS AND METHODS: FHIT mRNA was quantified by the validated realtime PCR (QPCR) in tumor samples of 84 CRC patients and mucosal biopsies of 15 adenomas, in comparison to 37 control patients, whereas subgroup of 57 CRC, 10 adenoma and 10 control cases were selected for immunohistochemical (IHC) detection of the native FHIT protein and LOH determination at FRA3B.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. DNA Primers. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Loss of Heterozygosity. Male. Middle Aged. Poland. Prospective Studies. RNA / biosynthesis. RNA / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083853.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


68. Vereczkey I, Tóth E, Orosz Z: [Diagnostic problems of ovarian mucinous borderline tumors]. Magy Onkol; 2009 Jun;53(2):127-33
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems of ovarian mucinous borderline tumors].
  • About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors.
  • The borderline tumor is a serious diagnostic and treatment problem both for the pathologists and for clinicians.
  • These tumors appeared to be intermediate in their histologic and prognostic features between the benign cystadenomas and clearly malignant carcinomas.
  • The borderline tumors occur most commonly in childbearing age, and show an indolent course.
  • To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases.
  • Eleven cases diagnosed as mucinous borderline ovarian tumor in our institute from 2000 to 2008 were reviewed.
  • Eight out of 11 were intestinal type while three were cervical (mullerian) type.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. GPI-Linked Proteins. Homeodomain Proteins / analysis. Humans. Keratin-20 / analysis. Keratin-7 / analysis. Membrane Glycoproteins / analysis. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581178.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 protein, human; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Glycoproteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / mesothelin
  •  go-up   go-down


69. Schildhaus HU, Büttner R, Binot E, Merkelbach-Bruse S, Wardelmann E: [Inflammatory fibroid polyps are true neoplasms with PDGFRA mutations]. Pathologe; 2009 Dec;30 Suppl 2:117-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory fibroid polyps are true neoplasms with PDGFRA mutations].
  • AIMS: Inflammatory fibroid polyps (IFP) are proliferations of CD34-positive spindle cells in the submucosa and mucosa of the gastrointestinal tract with an inflammatory infiltrate.
  • IFP occur in the stomach, small bowel, colon and esophagus.
  • METHODS: A total of 29 IFP originating in the stomach, small bowel and colon were examined immunohistochemically, and mutational analyses of PDGFRA exons 10, 12, 14 and 18 were conducted.
  • The mutational types are related to mutations known from gastrointestinal stromal tumors (GIST).
  • Our data indicate that IFP are true neoplasms (true benign tumors) and not reactive lesions.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Gastroenteritis / genetics. Gastrointestinal Neoplasms / genetics. Granuloma, Plasma Cell / genetics. Intestinal Polyps / genetics. Polyps / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Antigens, CD34 / genetics. Cell Division / genetics. Exons / genetics. Female. Gastric Mucosa / pathology. Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / pathology. Male. Mucous Membrane / pathology. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19756614.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


70. Koç M, Göçmen E, Kiliç M, Ozbay M, Oktem M, Tez M: Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology; 2006 Jul-Aug;53(70):616-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We measured serum endostatin levels of 30 patients aged between 34-83 years with gastric cancer and 30 patients without malignant pathology operated for benign pathologies with age ranging from 18 to 69.
  • Significantly higher serum endostatin levels were obtained in Lauren intestinal type tumors than Lauren diffuse type tumors.
  • CONCLUSIONS: These data suggest that serum endostatin levels do not correlate with clinicopathological parameters, except tumor histopathology (according to Lauren classification), in gastric cancer patients.
  • [MeSH-major] Angiogenesis Inhibitors / blood. Endostatins / blood. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995474.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins
  •  go-up   go-down


71. Hashimoto N, Hakamada K, Narumi S, Totsuka E, Aoki K, Kamata Y, Sasaki M: Heterotopic gastrointestinal mucosa and pancreatic tissue in a retroperitoneal tumor. J Hepatobiliary Pancreat Surg; 2006;13(4):351-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic gastrointestinal mucosa and pancreatic tissue in a retroperitoneal tumor.
  • We believe that this is the first report of a retroperitoneal tumor consisting of heterotopic gastrointestinal mucosa and pancreatic tissue.
  • Angiography revealed that the inferior vena cava was displaced by the hypovascular tumor.
  • The retroperitoneal lesion was diagnosed preoperatively as a benign tumor such as a neurogenic neoplasm or lymphangioma.
  • At laparotomy, a cystic tumor was found, which existed behind the inferior vena cava and renal vessels, and contained reddish-brown fluid, suggesting hemorrhage in the past.
  • The cut surface of the tumor showed a unilocular cyst with partially hypertrophic wall.
  • Histopathological examination revealed a cystic tumor lined with heterotopic gastric and duodenal mucosa, with pancreatic tissue in the muscularis propria.
  • In addition, evidence of bleeding from the gastric mucosa was observed in the cystic tumor.
  • External secretion from these tissues could have triggered the hemorrhage and expanded the tumor, possibly resulting in the back pain.
  • [MeSH-major] Back Pain / etiology. Choristoma / pathology. Gastric Mucosa. Intestinal Mucosa. Retroperitoneal Neoplasms / pathology. Vascular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Back Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858549.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • PATIENTS AND METHODS: Patients older than 16 years and diagnosed with intestinal intussusception between January 1990 and June 2006 were retrospectively reviewed.
  • RESULTS: Seventy-two patients underwent surgery for intestinal intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.
  • [MeSH-major] Intestinal Diseases / etiology. Intestinal Neoplasms / complications. Intussusception / etiology
  • [MeSH-minor] Abdominal Pain / etiology. Adenocarcinoma / complications. Adenoma / complications. Adolescent. Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Mucinous / complications. Female. Humans. Lipoma / complications. Lymphoma, Large B-Cell, Diffuse / complications. Male. Middle Aged. Peutz-Jeghers Syndrome / complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J, Taylor S, Nathke IS, Sansom OJ: Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene; 2010 Dec 09;29(49):6418-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the adenomatous polyposis coli (APC) tumour suppressor are the key initiating event of colorectal cancer.
  • Although the control of WNT signalling is well established as a central tumour-suppressive function, the significance of APC in regulating chromosome instability is less well established.
  • Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in models of benign (APC(Min/+) mouse) and invasive (AhCreER(+)APC(fl/+)PTEN(fl/fl)) cancer.
  • In contrast to intestinal enterocytes with a general SAC defect because of Bub1 (budding uninhibited by benzimidazole 1) deletion, APC-deficient enterocytes arrest equivalently to wild type when treated with Vinorelbine.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Adenomatous Polyposis Coli Protein / physiology. Antineoplastic Agents, Phytogenic / therapeutic use. Drug Resistance, Neoplasm / genetics. Paclitaxel / therapeutic use. Spindle Apparatus / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Aug;129(2):626-38 [16083717.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4609-22 [16030254.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2814-27 [16763565.001]
  • [Cites] J Cell Biol. 2007 Jan 15;176(2):183-95 [17227893.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):910-8 [17192415.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] J Cell Biol. 2007 Sep 24;178(7):1109-20 [17893240.001]
  • [Cites] Dev Cell. 2007 Oct;13(4):566-79 [17925231.001]
  • [Cites] J Cell Biol. 2008 Jun 2;181(5):719-26 [18519734.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):111-22 [18656424.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6314-28 [18694957.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1436-44 [19011632.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 May;49(1):1-15 [11309836.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] Cancer Cell. 2009 Oct 6;16(4):347-58 [19800579.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):378-84 [11514192.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1236-46 [15131783.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2978-91 [15075372.001]
  • [Cites] J Cell Biol. 2004 Jun 7;165(5):609-15 [15184397.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):e92 [15247325.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Onkologie. 1991 Feb;14(1):7-12 [2057177.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2972-7 [7606712.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1291-4 [7577038.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cell. 1999 Jan 8;96(1):79-88 [9989499.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53 [15561772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7286-91 [15857952.001]
  • (PMID = 20729907.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A7130; Canada / Canadian Institutes of Health Research / / 12858; United Kingdom / Cancer Research UK / / ; United Kingdom / Cancer Research UK / / CRUK/ 11243; United Kingdom / Cancer Research UK / / CRUK/ A11243; Canada / Canadian Institutes of Health Research / / 74711; United Kingdom / Cancer Research UK / / CRUK/ 11913
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Antineoplastic Agents, Phytogenic; 0 / Wnt Proteins; 5V9KLZ54CY / Vinblastine; EC 2.7.11.1 / Bub1 protein, mouse; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC3016607; NLM/ UKMS31064
  •  go-up   go-down


74. Yang Y, Nie X, Lu J, Lu XY, Wei YY, Wang H, Han ZH, Chen ZH, Zheng J: [Mixed epithelial and stromal tumor of kidney]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):29-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed epithelial and stromal tumor of kidney].
  • OBJECTIVE: To study the clinicopathological features and differential diagnoses of mixed epithelial and stromal tumor of the kidney.
  • METHODS: Clinical and pathological characteristics of 4 cases of mixed epithelial and stromal tumor of the kidney were studied.
  • Grossly the tumors had a solid and cyst appearance.
  • Microscopically, the tumors were composed of a mixture of stromal and epithelial elements.
  • One case showed Müllerian and intestinal epithelial differentiations.
  • Stromal elements essentially consisted of spindle cells, with thick-walled blood vessels and bands of smooth muscle cells as distinctive features of the tumor.
  • CONCLUSIONS: Mixed epithelial and stromal tumor of the kidney is a benign neoplasm with distinct histopathological features.
  • It should be distinguished from many other renal neoplasms.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


75. Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL: Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol; 2009 Jul;114(1):75-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two contemporary controls who underwent extrafascial abdominal hysterectomy for benign disease were identified for each subject.
  • [MeSH-major] Hysterectomy / adverse effects. Intestinal Diseases / etiology. Urinary Bladder Diseases / etiology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Emotions. Female. Humans. Life Style. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urinary Incontinence / etiology


76. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg; 2008 Aug;207(2):210-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
  • BACKGROUND: The histology and clinical behavior of ampullary tumors vary substantially.
  • We speculated that this might reflect the presence of two kinds of ampullary adenocarcinoma: pancreaticobiliary and intestinal.
  • STUDY DESIGN: We analyzed patient demographics, presentation, survival (mean followup 44 months), and tumor histology for 157 consecutive ampullary tumors resected from 1989 to 2006.
  • RESULTS: There were 33 benign (32 adenomas and 1 paraganglioma) and 124 malignant (118 adenocarcinomas and 6 neuroendocrine) tumors.
  • Size of tumor did not predict survival, nor did cribriform/papillary features, dirty necrosis, apical mucin, or nuclear atypia.
  • Patients with pancreaticobiliary ampullary adenocarcinomas presented with jaundice more often than those with the intestinal kind (p = 0.01) and had worse survival.
  • CONCLUSIONS: In addition to other factors, tumor type (intestinal versus pancreaticobiliary) had a major effect on survival in patients with ampullary adenocarcinoma.
  • Intestinal ampullary adenocarcinomas behaved like their duodenal counterparts, but pancreaticobiliary ones were more aggressive and behaved like pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Jaundice, Obstructive / mortality. Jaundice, Obstructive / pathology. Jaundice, Obstructive / surgery. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656049.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Manipadam MT, Singh R, Vijay A: Dedifferentiated liposarcoma presenting as jejunal polyp. Case report. APMIS; 2007 Dec;115(12):1450-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary jejunal dedifferentiated liposarcoma presenting as a submucosal polyp mimicking a benign neoplasm.
  • The use of MDM2 immunostaining in differentiating benign lipomatous tumours from well-differentiated liposarcomas is mentioned, which is of value especially in lipomatous tumours of the gut where ulcerated benign tumours can show varying degrees of atypia.
  • [MeSH-major] Intestinal Polyps / pathology. Jejunal Neoplasms / pathology. Liposarcoma / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184419.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


78. Ruiz-Tovar J, Reguero-Callejas ME, González Palacios F: Inflammation and perforation of a solitary diverticulum of the cecum. A report of 5 cases and literature review. Rev Esp Enferm Dig; 2006 Nov;98(11):875-80
MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary diverticulum of the cecum is a benign condition uncommon in the Western world, and with a higher incidence in Asian population.
  • In spite of the information provided by ultrasonography or CT scans, a correct preoperative diagnosis is still difficult to reach, and is usually arrived at in the operating theater; differentiation from a neoplasm may be also sometimes complicated, and a wide surgical resection is usually required for such cases.
  • [MeSH-major] Diverticulitis, Colonic / complications. Diverticulum, Colon / complications. Intestinal Perforation / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198478.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Alebouyeh M, Moussavi F, Tabari AK, Vossough P: Aggressive intra-abdominal fibromatosis in children and response to chemotherapy. Pediatr Hematol Oncol; 2005 Sep;22(6):447-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-abdominal fibromatosis (IAF) is a rare benign neoplasm arising from the abdominal fibrous tissue, mostly in the mesentery.
  • The authors report on a boy who presented with a large IAF at the age of 5 years.
  • Within 6 months after initial presentation, he underwent 4 subsequent abdominal explorations for diagnosis, tumor reduction, and intestinal obstructions.
  • Due to accelerated tumor growth and deteriorated general condition, as a last resort, a chemotherapy trial with vincristin and methotrexate was carried out.
  • This regimen proved to be effective in reducing the tumor burden and improving the patient's general condition.
  • Outcome of IAF depends on early diagnosis and complete tumor resection, and, if indicated, timely employment of neo/adjuvant chemotherapy.
  • [MeSH-minor] Child, Preschool. Humans. Male. Methotrexate / administration & dosage. Tumor Burden / drug effects. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169811.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement